ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 114 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2024. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $403,575 | -35.6% | 36,195 | -14.0% | 0.01% | -38.5% |
| Q4 2023 | $627,004 | +192.8% | 42,109 | -5.6% | 0.01% | +160.0% |
| Q3 2023 | $214,124 | -36.1% | 44,609 | 0.0% | 0.01% | -28.6% |
| Q2 2023 | $335,014 | +66.2% | 44,609 | 0.0% | 0.01% | +75.0% |
| Q1 2023 | $201,633 | -59.9% | 44,609 | 0.0% | 0.00% | -60.0% |
| Q4 2022 | $502,744 | +17.7% | 44,609 | -0.0% | 0.01% | +11.1% |
| Q3 2022 | $427,000 | +25.6% | 44,612 | +6.4% | 0.01% | +50.0% |
| Q2 2022 | $340,000 | – | 41,933 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $108,154,164 | 38.37% |
| Vivo Capital, LLC | 4,220,048 | $47,053,535 | 3.70% |
| Vestal Point Capital, LP | 2,610,000 | $29,101,500 | 2.41% |
| MPM BioImpact LLC | 1,268,471 | $14,143,452 | 2.27% |
| Redmile Group, LLC | 4,326,509 | $48,240,575 | 1.77% |
| Cormorant Asset Management, LP | 3,142,079 | $35,034,181 | 1.54% |
| Orbimed Advisors | 2,717,970 | $30,305,366 | 0.56% |
| Nan Fung Group Holdings Ltd | 41,950 | $467,743 | 0.43% |
| Financial Advisory Group | 31,417 | $350,300 | 0.06% |
| Forefront Analytics, LLC | 10,261 | $114,412 | 0.06% |